251. Urea cycle disorder Clinical trials / Disease details
Clinical trials : 54 / Drugs : 61 - (DrugBank : 15) / Drug target genes : 3 - Drug target pathways : 28
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03064048 (ClinicalTrials.gov) | September 15, 2017 | 10/2/2017 | Nitric Oxide Supplementation on Neurocognitive Functions in Patients With ASLD | Effect of Nitric Oxide (NO) Supplementation on Neurocognitive Measures in Argininosuccinate Lyase Deficiency (ASLD) | Argininosuccinate Lyase Deficiency;Urea Cycle Disorder;Urea Cycle Disorders, Inborn;Argininosuccinic Aciduria | Dietary Supplement: Neo-ASA;Dietary Supplement: Placebo | Baylor College of Medicine | Rare Diseases Clinical Research Network;Neogenis Laboratories | Completed | 6 Years | 50 Years | All | 16 | N/A | United States |